EMA recommends European approval for Zealands Pharma pen out-licensed to Novo Nordisk

Zegalogue for the treatment of severe hypoglycaemia in diabetic patients was approved in the US in March 2021.
Adam Steensberg kan som adm. direktør i Zealand Pharma glæde sig til en kommende godkendelse i EU, der som regel er en formsag efter en anbefaling fra EMA's ekspertkomité CHMP. | Photo: Stine Bidstrup
Adam Steensberg kan som adm. direktør i Zealand Pharma glæde sig til en kommende godkendelse i EU, der som regel er en formsag efter en anbefaling fra EMA's ekspertkomité CHMP. | Photo: Stine Bidstrup
by MARKETWIRE ‎

Zealand Pharma has received a thumbs up for Zegalogue from a panel of experts at the European Medicines Agency (EMA).

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Foto: Mike Blake/Reuters/Ritzau Scanpix

    Gilead Sciences CMO to leave early 2025

    For subscribers

    Further reading